A calculation you should do twice and write down once

Choosing the diluent volume is a real decision and it is usually made by habit. A larger volume gives a lower concentration and larger injection volumes, which are easier to measure accurately and slower to exhaust the vial. A smaller volume gives a concentrated solution and tiny injection volumes, which are more sensitive to graduation error, dead space and the small losses of ordinary technique. There is no universally correct answer, but the direction of the trade-off is unambiguous and it runs against the instinct to use as little water as possible.

Dead space, air and the dose that stays behind

Dead space is the volume held in the needle and hub after the plunger has bottomed out. For a fixed-needle insulin syringe it is very small, of the order of two to seven microlitres. For a detachable needle on a conventional luer fitting it is considerably larger, sometimes exceeding fifty microlitres.

Whether that matters is a question of proportion. At an intended volume of two hundred microlitres, a five-microlitre loss is under three per cent and irrelevant. At an intended volume of twenty microlitres — which a concentrated reconstitution produces — the same loss is a quarter of the dose. This is one of the strongest practical arguments against making a vial up to a very high concentration: it pushes the injection volume down into the range where fixed losses dominate.

Air bubbles interact with the same arithmetic. A bubble displaces solution, so a barrel drawn to eight units containing a one-unit bubble delivers seven units of drug. Small bubbles in a subcutaneous injection are not a safety problem in the way they would be intravenously; they are a dosing problem. Expelling them by tapping the barrel upright and pushing the plunger to the mark is a volumetric correction, not a ritual, and it matters most at exactly the small volumes where people are least inclined to bother.

The arithmetic, in four lines

Concentration equals mass of peptide divided by volume of diluent. Injection volume equals intended dose divided by concentration. Units equal injection volume in millilitres multiplied by one hundred. Micrograms per unit equals concentration in micrograms per millilitre divided by one hundred.

Worked once: a 5 mg vial made up with 1.0 mL of diluent is 5 mg/mL, which is 5,000 micrograms per millilitre, which is 50 micrograms per unit. A 250 microgram dose is 0.05 mL, which is five units.

Worked again with a different diluent volume: the same 5 mg vial made up with 2.0 mL is 2.5 mg/mL, which is 25 micrograms per unit. The same 250 microgram dose is now ten units. The vial has not changed and the dose has not changed; the unit count has doubled because the concentration halved.

That pair of examples is the whole argument for recalculating at every vial. A person who established five units as their dose and then made the next vial up with twice the water, keeping five units, halved their dose without any step in the process appearing wrong. The Journal recommends writing the microgram-per-unit figure on the vial in permanent marker, because it is the number that changes and the one nobody remembers changing.

What the diluent changes, and what it does not

The diluent has no effect on the arithmetic and a substantial effect on everything else. Bacteriostatic water contains a preservative, conventionally benzyl alcohol at around nine tenths of a per cent, which inhibits microbial growth and is what makes repeated puncture of a multi-dose vial defensible. Sterile water for injection contains no preservative and offers no protection after the first puncture. Sodium chloride solution is isotonic and generally more comfortable on injection, and preserved and unpreserved presentations both exist.

The choice is therefore a sterility decision rather than a convenience one. A vial that will be entered more than once and kept for weeks is a different proposition from a single-use preparation, and the presence or absence of a preservative is the difference.

Two cautions belong here. Benzyl alcohol is not appropriate in all populations and is specifically avoided in neonates. And no preservative rescues poor technique: bacteriostatic means growth-inhibiting, not sterilising, and a stopper swabbed carelessly with a needle passed through a wet surface will introduce organisms that the preservative was never intended to handle. The diluent is a margin, not a permission.

Common vial strengths, worked

For a 2 mg vial: 1.0 mL of diluent gives 2 mg/mL and 20 micrograms per unit; 2.0 mL gives 1 mg/mL and 10 micrograms per unit. For a 5 mg vial: 1.0 mL gives 50 micrograms per unit; 2.0 mL gives 25; 2.5 mL gives 20. For a 10 mg vial: 1.0 mL gives 100 micrograms per unit; 2.0 mL gives 50; 5.0 mL gives 20.

Reading in the other direction: at 50 micrograms per unit, a 250 microgram dose is five units, a 500 microgram dose is ten, a 1 mg dose is twenty. At 100 micrograms per unit those become two and a half, five and ten. The half unit in that first case is not measurable on a barrel graduated in single units, which is a small illustration of how concentration choice constrains what doses can actually be given.

The general principle is to choose a diluent volume that puts your intended doses on whole, comfortably readable graduations across the whole escalation range you expect to use, and then to leave it alone. Choosing a concentration that makes the current dose convenient and the next three doses awkward is a common and avoidable annoyance.¹

The stale calculation

The commonest arithmetic failure in this market is not a miscalculation. It is a correct calculation that has quietly expired. Vials change strength between batches and between suppliers. Diluent volume changes because a different measuring device was used, or because the previous figure was not written down. Neither event produces any visible signal.

Three structural habits prevent it, and exhortations to care do not. Write the concentration and the microgram-per-unit figure on the vial, on tape, at the moment of reconstitution. Recalculate at every new vial from the stated mass and the measured diluent volume, rather than reusing the previous unit count. And do not change syringe barrel size and vial concentration in the same week, because if something then goes wrong there is no way to tell which change caused it.

The Journal notes that this is exactly the class of error a dispensing pharmacist exists to catch, and that in a market where material arrives as unlabelled powder there is no pharmacist. Structural checks are not a counsel of perfection here; they are the only remaining layer.

Gauge, angle and whether to pinch

Gauge describes bore: higher numbers are thinner. Insulin syringes are commonly twenty-nine to thirty-one gauge and pen needles run to thirty-two or thirty-four. Thinner needles are more comfortable and flow more slowly. For an aqueous peptide solution the flow penalty is minor; for anything viscous it becomes real, and the practical failure is that people push harder and lose control of the plunger.

Angle and skin-pinch technique follow from length. With a 4 mm needle, insertion perpendicular to the skin without a pinch is appropriate, because there is no plausible way to reach muscle. With longer needles a lifted skin fold is required in order to raise the subcutaneous layer away from muscle, and the fold must be released only after the needle is withdrawn — releasing early while the needle is in situ defeats the purpose.²

The habit of injecting at forty-five degrees is a legacy of long needles and is a poor default with short ones, because an oblique 4 mm track can end intradermally. The Journal states the simple version: short needle, ninety degrees, no pinch, and there is then very little left to get wrong about depth.

The tenfold error in detail

It arises from the fact that one hundred units and one millilitre are the same volume. A calculated injection volume of 0.1 mL is ten units. A person who reads 0.1 and draws to the mark labelled one has given a tenth of the intended dose; a person who reads ten units and draws to the 1.0 mL mark on a millilitre-graduated barrel has given ten times it.

The vector is almost always a syringe that is not an insulin syringe. Tuberculin syringes and general-purpose 1 mL syringes are the same length, the same colour and often the same price, and they are graduated in hundredths of a millilitre. Nothing about picking up the wrong one feels like an error.

Two structural defences work. Keep one syringe type and one barrel size, and buy them deliberately rather than taking whatever the supplier included. And express the dose in the units of the instrument in use — write "8 units" on the vial tape if you use insulin syringes, and never carry a millilitre figure and a unit figure in the same note where one can be read as the other.

The Journal treats this as the most important paragraph in the file. It is a boring failure with a large magnitude, which is the profile of most real harm in this market.

The arithmetic is only as good as the label

Every calculation above starts from a stated mass of peptide in the vial. For licensed product that figure is a release specification. For research-grade lyophilised powder it is a claim, and the difference matters because the claim sits at the front of every subsequent computation.

Two distinct quantities are involved. Chromatographic purity is the proportion of peptide-related material that is the intended peptide. Peptide content is the fraction of the vial mass that is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain materially less peptide than labelled, and content is the number that determines a dose.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content less consistently. Several vendors, among them WXT, SSA, CPC, SWB and MKM, publish per-batch reports; others publish nothing verifiable. Where content has not been measured, the labelled mass should be treated as an upper bound and the resulting dose figure as an estimate. That is unsatisfying and it is honest, and it is why the Journal has argued in Analytics for content and endotoxin as standard reported fields.

How the Journal reports technique

Two bodies of evidence underlie this file. Questions of tissue, depth, needle length and rotation come from the insulin injection-technique literature, which is large, well conducted and directly transferable because it concerns anatomy rather than any particular molecule. Questions of absorption by site, in-use stability and exposure come from the incretin literature, which is smaller and where we say so. Where we describe practice rather than evidence, the text states it.

We give arithmetic in full rather than in tables of pre-computed unit counts, deliberately. A pre-computed table is correct only for the concentration it was computed for, and the recurring error in this market is precisely the reuse of a correct number under changed conditions. A reader who can perform the four-line calculation is protected against a class of error that no table can prevent.

Nothing in this file is medical advice. The Journal does not recommend doses, products, diluents or suppliers, and cannot assess an individual. Several compounds discussed are sold for research use only, are not approved for human use in any jurisdiction, and are not manufactured or released to any human sterility, content or endotoxin standard. Injection technique is properly taught in person by a clinician or nurse, and this file is not a substitute for that.

Four things about this that are genuinely unestablished

First, the in-use stability of home-reconstituted peptides. No sequence-specific, buffer-specific, container-specific stability study exists for the great majority of what is sold in this market, and the figures in circulation are extrapolations.

Second, whether the injection-site interchangeability established for licensed acylated agonists holds for material of uncertain formulation. The mechanism suggests it should; nobody has measured it.

Third, the real-world frequency of the errors catalogued above. Our ranking comes from correspondence, which is a self-selected sample that over-represents people who noticed. The denominator is unknown.

Fourth, whether any of the technique measures described here changes outcomes in this specific population. They are supported by anatomical evidence and by the insulin literature; a trial in incretin users has not been done and probably will not be.²

Readers who know of stability data or technique trials we have missed should write to standards@compoundjournal.com. This is one of the files where we would most like to be corrected, because the current state is that millions of injections a week are being given on the basis of transferred evidence and a four-line calculation.

Technique is the least glamorous subject this publication covers and, measured by the number of things that can go wrong per week, one of the most consequential. A person can read every trial in the class, choose a molecule intelligently, titrate patiently, and then give themselves a tenth of the intended dose because two syringes in a drawer were graduated on different scales. The pharmacology is not what fails in that story.